Antiretroviral treatment adherence and its determinants in Sub-Saharan Africa: A prospective study at Yaounde Central Hospital, Cameroon

AIDS Research and Therapy

Volumn 6, Issue , 2009, Pages

  Rougemont, Mathieu ^a   Stoll, Beat E ^a   Elia, Nadia ^a   Ngang, Peter ^b  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b CNPS Hospital   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AFRICA SOUTH OF THE SAHARA; ARTICLE; CAMEROON; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF REPORT; SEX DIFFERENCE; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 77954696442     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-6-21     Document Type: Article

References (32)

1. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006, 368(9534):505-510. 10.1016/S0140-6736(06)69158-7, 16890837.
2. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, Nash D, Schechter M, Laurent C, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 2008, 86(7):559-67. 10.2471/BLT.07.044248, 2647487, 18670668.
3. Van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 2005, 10(5):464-470. 10.1111/j.1365-3156.2005.01409.x, 15860093.
4. Laurent C, Meilo H, Guiard-Schmid JB, Mapoure Y, Noel JM, M'Bangue M, et al. Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis 2005, 41(1):108-111. 10.1086/430712, 15937770.
5. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007, 4(10):e298. 10.1371/journal.pmed.0040298, 2020494,2020494, 17941716.
6. Demographic and Health Surveys Cameroon 2004. 2009, http://www.measuredhs.com/countries/metadata.cfm?surv_id=232&ctry_id=4&SrvyTp=ctry
7. Laniece I, Ciss M, Desclaux A, Diop K, Mbodj F, Ndiaye B, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 2003, 17(Suppl 3):S103-S108. 10.1097/00002030-200317003-00014, 14565616.
8. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003, 17(9):1369-1375. 10.1097/00002030-200306130-00011, 12799558.
9. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, Makhema J, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 2003, 34(3):281-288. 10.1097/00126334-200311010-00004, 14600572.
10. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, Calmy A, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004, 364(9428):29-34. 10.1016/S0140-6736(04)16586-0, 15234853.
11. Attaran A. Adherence to HAART: Africans take medicines more faithfully than North Americans. PLoS Med 2007, 4(2):e83. 10.1371/journal.pmed.0040083, 1808103, 17326715.
12. Weidle PJ, Wamai N, Solberg P, Liechty C, Sendagala S, Were W, et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006, 368(9547):1587-1594. 10.1016/S0140-6736(06)69118-6, 17084759.
13. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006, 296(6):679-690. 10.1001/jama.296.6.679, 16896111.
14. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006, 3(11):e438. 10.1371/journal.pmed.0030438, 1637123,1637123, 17121449.
15. Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health 2008, 8:265. 10.1186/1471-2458-8-265, 2518153, 18667066.
16. Etard JF, Laniece I, Fall MB, Cilote V, Blazejewski L, Diop K, et al. A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients. Trop Med Int Health 2007, 12(10):1191-1198. 10.1111/j.1365-3156.2007.01910.x, 17956501.
17. Falagas ME, Zarkadoulia EA, Pliatsika PA, Panos G. Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature. Retrovirology 2008, 5:13. 10.1186/1742-4690-5-13, 2267456, 18241330.
18. Karcher H, Omondi A, Odera J, Kunz A, Harms G. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop MedInt Health 2007, 12(5):687-94.
19. Mosoko JJ, Akam W, Weidle PJ, Brooks J, Aweh A, et al. Survival and adherence to ART in an era of decreasing drug cost in Limbe, Cameroon. 14th Conference on Retroviruses and Opportunistic Infections. (CROI); 2007 25-28 February; Los Angeles, California Abstract 536.
20. Ollivier F, N'Kam M, Midoungue C, Rey JL. Study conducted at the Yaounde University Hospital on anti-retroviral treatment compliance (Cameroon). Sante Publique 2005, 17(4):559-568. 10.3917/spub.054.0559, 16485437.
21. Nachega JB, Lehman DA, Hlatshwayo D, Mothopeng R, Chaisson RE, Karstaedt AS. HIV/AIDS and antiretroviral treatment knowledge, attitudes, beliefs, and practices in HIV-infected adults in Soweto, South Africa. J Acquir Immune Defic Syndr 2005, 38(2):196-201. 10.1097/00126334-200502010-00011, 15671805.
22. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, Makhema J, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 2003, 34(3):281-288. 10.1097/00126334-200311010-00004, 14600572.
23. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000, 12(3):255-266. 10.1080/09540120050042891, 10928201.
24. Wester CW, Bussmann H, Avalos A, Ndwapi N, Gaolathe T, Cardiello P, et al. Establishment of a public antiretroviral treatment clinic for adults in urban Botswana: lessons learned. Clin Infect Dis 2005, 40(7):1041-1044. 10.1086/428352, 15824998.
25. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008, 5(5):e109. 10.1371/journal.pmed.0050109, 2386831,2386831, 18494555.
26. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000, 12(3):255-266. 10.1080/09540120050042891, 10928201.
27. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002, 34(8):1115-1121. 10.1086/339074, 11915001.
28. Fielding KL, Charalambous S, Stenson AL, Pemba LF, Martin DJ, Wood R, Churchyard GJ, Grant AD. Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis 2008, 16(8):93.
29. Singh N, Berman SM, Swindells S, Justis JC, Mohr JA, Squier C, Wagener MM. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999, 29(4):824-830. 10.1086/520443, 10589897.
30. Chen SC, Yu JK, Harries AD, Bong CN, Kolola-Dzimadzi R, Tok TS, King CC, Wang JD. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health 2008, 13(4):513-519. 10.1111/j.1365-3156.2008.02029.x, 18282238.
31. Laurent C, Bourgeois A, Mpoudi-Ngole E, Ciaffi L, Kouanfack C, Mougnutou R, et al. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS Res Hum Retroviruses 2008, 24(3):393-399. 10.1089/aid.2007.0219, 18327976.
32. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006, 43(6):770-6. 10.1086/507095, 16912954.